Login to Your Account

NewCo News: Ersatta Shows Promise for Complications of Diabetes

By Catherine Shaffer

Tuesday, July 26, 2011
A peptide once thought to be irrelevant and superfluous in Type I diabetes is receiving renewed attention thanks to the efforts of Cebix Inc., a La Jolla, Calif.-based company focused on complications of diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription